2022-10-21

ROI-NJ: BD’s new Onclarity HPV test greatly improves standard of care for women

ROI-NJ: BD’s new Onclarity HPV test greatly improves standard of care for women

Molly Broache, Associate Director, Medical Affairs for US IDS explains how the BD Onclarity™ HPV Assay positively impacts public health by providing a more precise estimate of a woman’s risk of cervical precancer and cancer.

Latest resources

Discover our latest articles, webinars, press releases and updates in women's health.

physician and patient
New Harris Poll Finds Women Want More Education on Sexually Transmitted Infections Testing and Treatment
BD Onclarity™ HPV Assay with extended genotyping
Cervical Cancer | Brochures
BD Onclarity™ HPV Assay with extended genotyping
Fast Company op-ed
Cervical Cancer | News & Updates
POV: The U.S. healthcare system is failing Black and Latina women